OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $255,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost bought 150,000 shares of the company's stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average price of $1.70 per share, with a total value of $255,000.00. Following the transaction, the chief executive officer now directly owns 213,651,448 shares in the company, valued at $363,207,461.60. This represents a 0.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, April 1st, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $165,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The stock was acquired at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was bought at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Price Performance

Shares of OPKO Health stock remained flat at $1.66 on Tuesday. 2,570,780 shares of the company's stock traded hands, compared to its average volume of 4,070,057. The firm has a 50 day moving average price of $1.69 and a 200-day moving average price of $1.58. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.11 billion, a PE ratio of -8.74 and a beta of 1.70. OPKO Health, Inc. has a 52 week low of $1.15 and a 52 week high of $2.04.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. On average, analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OPK has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, March 19th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. Finally, StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd.

Institutional Investors Weigh In On OPKO Health

Large investors have recently bought and sold shares of the company. Millennium Management LLC grew its holdings in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after buying an additional 2,112,382 shares during the period. Lazard Asset Management LLC raised its holdings in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after acquiring an additional 1,502,342 shares during the period. Altshuler Shaham Ltd bought a new position in shares of OPKO Health during the fourth quarter worth approximately $2,082,000. Norges Bank bought a new position in OPKO Health during the fourth quarter worth about $1,657,000. Finally, Two Sigma Investments LP boosted its holdings in OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after purchasing an additional 949,671 shares during the period. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.